Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase ...

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Twenty-three patients received ...

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With ...

All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk myelodysplastic syndromes (MDS) ...

Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...

Azacitidine is incorporated predominantly—around 80% to 90%—not into DNA, but into RNA, which causes damage. The researchers have now demonstrated that damage in messenger RNA (mRNA), which transports ...

Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid ...

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...

Chemotherapeutics are designed to damage cancer cells in a targeted manner - often by targeting their genetic material. The drug azacitidine, for example, has been used for decades to treat two types ...

LMU researchers show that the chemotherapeutic drug azacitidine damages RNA and reveal a possible approach to improve therapies. Chemotherapeutics are designed to damage cancer cells in a targeted ...